A medical oncologist called the late-stage clinical trial results “remarkable,” though Sasse said the drug means his body ...
Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver hormone therapy, according to the results of a large clinical trial led by UCL ...
Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver hormone therapy, according to the results of a large clinical trial led by UCL ...
But what makes Tewari compelling is not just the scale of his achievement. It is the moral clarity with which he speaks about ...
2don MSN
8-hour prostate cancer surgery, back on his feet next day - a breakthrough in modern cancer care
A 64-year-old with advanced prostate cancer underwent robotic surgery after hormonal therapy, achieving successful tumour ...
NAPT recognized Dr. Frank at the 2026 NPC with its Accelerator Award for Clinical Achievement, honoring exceptional clinicians who demonstrate leadership in proton therapy and play a pivotal role in ...
Health issues in Black communities are shaped by social, environmental, and genetic factors. Understanding and managing these ...
From his perspective, one of the most persistent misconceptions in prostate cancer care relates to how patients interpret ...
Transdermal estradiol patches and LHRH agonists led to similar metastasis-free and overall survival in locally advanced prostate cancer. Estradiol was associated with substantially lower incidence of ...
ADT intensification may not improve prostate cancer survival. Explore real-world findings and key risk factors. Read more.
Transdermal estradiol (tE2) is an alternative to luteinizing hormone–releasing hormone (LHRH) agonists as androgen-deprivation therapy in patients with prostate cancer. With tE2, testosterone is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results